This bulletin focuses on alogliptin which is the fifth dipeptidylpeptidase-4 (DPP-4) inhibitor licensed in the UK. The document includes recommendations to ensure prescribing is in line with NICE guidance, considers clinical effectiveness in relation to dual therapy and triple therapy, combination products and also safety considerations. The resource includes a GP decision aid, data collection form and patient invite for diabetes review.
